BXT Stock Chart & Stats
€0.22
>-€0.01(-2.67%)
At close: 4:00 PM EDT
€0.22
>-€0.01(-2.67%)
Day’s Range― - ―
52-Week Range€0.17 - €0.62
Previous CloseN/A
Volume10.42K
Average Volume (3M)23.63K
Market Cap
€28.39M
Enterprise Value€49.67
Total Cash (Recent Filing)€1.20M
Total Debt (Recent Filing)€6.69M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding136,093,150
10 Day Avg. Volume34,106
30 Day Avg. Volume23,633
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Cash BurnThe reduction in operating cash outflow is a modest improvement in resource consumption and could extend funding runway if maintained. However, cash generation remains negative, so this benefit is primarily that the pace of deterioration has eased rather than evidence of self-sustaining operations.
Asset Base IncreasedAn expanding asset base can provide a broader platform for future commercialization and may indicate that the company still has operating resources to deploy. The benefit is limited because assets remain substantially below debt, so this improvement does not resolve the company’s stressed capitalization.
Positive Reported EPS GrowthReported positive EPS growth provides a limited indication that per-share earnings performance has improved on the selected measurement basis. This could support future operating progress if sustained, although the company continues to report substantial losses and has not yet demonstrated a durable path to profitability.
Bears Say
Revenue CollapseRevenue has effectively disappeared, leaving the business without a meaningful recurring top-line base to absorb operating costs or fund development. Until sales recover materially, the company has limited evidence of commercial traction, making future profitability and internally funded growth highly uncertain.
Persistent Large LossesLarge continuing net losses show that the current operating model is not covering its cost base, while the worsening TTM loss indicates that profitability remains distant. Persistent losses can consume capital and increase reliance on financing, constraining strategic flexibility over the coming quarters.
Stressed Solvency And LeverageDebt materially exceeds the asset base and negative shareholder equity reflects accumulated losses and weak capitalization. This combination limits financial flexibility, increases dependence on external funding, and leaves less capacity to withstand continued operating weakness or finance expansion on favorable terms.
BioNxt Solutions News
BXT FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was €0.17 and its highest was €0.62 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is €28.39M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is Nov 27, 2026 which is in 79 days.
How were BioNxt Solutions’s earnings last quarter?
BioNxt Solutions released its earnings results on Aug 28, 2026. The company reported -€0.006 earnings per share for the quarter.
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 136,093,150 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
BioNxt Solutions reported an EPS of -€0.006 in its last earnings report. Following the earnings report the stock price went up 6.818%.
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in DE:BXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, including transdermal patches and oral dissolvable films, specifically for neurological medications. It also advances psychedelic medicine applications to treat various mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Furthermore, BioNxt is engaged in creating point-of-care diagnostics, comprising rapid tests and biosensor screening tools, aimed at early disease detection, improved treatment efficacy, and enhanced disease management. This diagnostic portfolio features a COVID-19 PCR kit, alongside oral biosensors for peri-implantitis, H1N1 (swine flu), and H5N1 (avian flu). Complementing its development efforts, the company provides analytical testing and consulting services, and is involved in pathogen and oral health diagnostics, thin film drug formulation, and the production and formulation of psychedelic pharmaceuticals. The company adopted its current name in November 2022, having previously been known as XPhyto Therapeutics Corp.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Avicanna
―
InnoCan Pharma
―